
The World Market for Liquid Biopsy, 2023
Description
The World Market for Liquid Biopsy, 2023
Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.
Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.
This report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:
The Market for Liquid Biopsy by Region
On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:
In addition, the report profiles key companies in the market, including:
Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the Liquid Biopsy Market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.
Liquid biopsy is gaining acceptance each year. Even through the COVID-19 pandemic, announcements of new liquid biopsy products were made and studies conducted to assess the capability of these tests in clinical diagnostics uses. While tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors, they have risks and limitations and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care.
This report, The World Liquid Biopsy Market, 2023, from Kalorama Information, contains up-to-date information and useful data points for business planning:
The Market for Liquid Biopsy by Region
- North America
- Europe
- Asia
- Rest of World
- Growth to 2027
- Growth to 2027
- Growth to 2027
- Growth to 2027
- Growth to 2027
- Breast
- Lung
- Colorectal
- Ovarian
- Prostate
- Pan-Cancer
- Other Cancer
On the Market: Selected Market-Available CTC-based Liquid Biopsy Tests, 2021
On the Market: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2021
Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:
- Early detection and diagnosis / screening
- Alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
- Therapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
- Disease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
In addition, the report profiles key companies in the market, including:
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- Angle, PLC
- Aspira Women’s Health
- Biocartis Group Nv
- Biocept, Inc.
- Biodesix
- Cellmax Life
- Circulogene
- Diacarta, Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- Gilupi Gmbh
- Grail (Illumina)
- Guardant Health, Inc.
- Hologic
- Lunglife AI (Formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, SPA
- Myriad Genetics, Inc.
- Natera, Inc.
- Neogenomics Laboratories, Inc.
- Oncocyte Corporation
- Oncodna S.A.
- Personal Genome Diagnostics
- Qiagen N.V.
- Cell-Free DNA Technologies
- Ctc Technologies
- Exosome And Mirna Technologies
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- Volitionrx
Table of Contents
211 Pages
- Introduction
- Liquid Biopsy Technologies
- Industry Structure
- Liquid Biopsy Market Revenues and Forecast
- Introduction
- Current Major Liquid Biopsy Technologies
- Introduction
- Advantages and Limitations of ctDNA in Liquid Biopsy
- Current ctDNA-based Liquid Biopsy Tests
- ctDNA-based Liquid Biopsy Tests in Development
- Introduction
- Challenges in the Development of CTC-based Liquid Biopsy Tests
- CTC-based Liquid Biopsy Tests
- Selected CTC-based Liquid Biopsy Tests in Development
- Introduction
- Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
- Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
- Introduction
- Liquid Biopsy Tests Based on Multiple Analytes
- Multiple Analyte-based Liquid Biopsy Tests in Development
- Introduction
- Liquid Biopsy Tests for Research Use Only
- Introduction
- Tiers of Competition
- Competitive Factors
- Significant Market Trends
- Competitors No Longer in the Liquid Biopsy Market
- Market Overview
- Market Forecast
- Circulating Tumor DNA
- Circulating Tumor Cells
- Extracellular Vesicles and Other Analytes
- Multiple Analytes
- Therapy Guidance and Monitoring
- Diagnosis/Screening
- Disease Prognosis
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Ovarian Cancer
- Prostate Cancer
- Other Cancers
- Pan-Cancer Tests
- Companies in the Market
- Adaptive Biotechnologies
- Agena Bioscience, Inc.
- ANGLE, plc
- Aspira Women’s Health
- Biocartis Group NV
- Biocept, Inc.
- Biodesix
- CellMax Life
- Circulogene
- DiaCarta, Inc.
- Epic Sciences
- Epigenomics AG
- Exact Sciences
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc. (Roche)
- Freenome, Inc.
- GILUPI GmbH
- GRAIL (Illumina)
- Guardant Health, Inc.
- Hologic
- LungLife AI (formerly Cynvenio Biosystems)
- Menarini-Silicon Biosystems, Spa
- Myriad Genetics, Inc.
- Natera, Inc.
- NeoGenomics Laboratories, Inc.
- Oncocyte Corporation
- OncoDNA S.A.
- Personal Genome Diagnostics
- QIAGEN N.V.
- Resolution Biosciences (Agilent)
- Roche Diagnostics
- Sysmex-Inostics, Inc.
- Tempus
- VolitionRx
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.